A Message from Our Founder & Executive Chairman

Welcome to Jiaxing Jingyin Biotechnology Group.

I am Dr. Xianghao Zhang, Founder and Executive Chairman of Jingyin Biotech Group.

My career in dentistry began at the Peking University School and Hospital of Stomatology, where years of academic training and clinical practice shaped my belief that healthcare is ultimately about improving lives. Working alongside dedicated clinicians, I witnessed both the remarkable progress of modern dentistry and the limitations of conventional dental materials. These experiences inspired my commitment to advancing biomaterials and ultimately led to the founding of Jingyin Biotech Group.

In 2011, I established Beijing OKVD Biotechnology Co., Ltd., followed by Jiaxing Jingyin Biotechnology Group in 2020, with a clear vision: to develop innovative biomaterials that enhance clinical performance and improve patient care. Since then, we have remained committed to the research, development, and manufacturing of high-quality dental biomaterials. Through continuous innovation and advanced material science, we strive to address long-standing clinical challenges and deliver reliable solutions for dental professionals worldwide.

Over the past decade, together with Dr. Weiping Zeng, a distinguished biomaterials expert returning from Japan, we have built a strong innovation platform supported by an integrated manufacturing network across Beijing, Zhejiang, and Guangdong. Today, Jingyin Biotech Group holds 17 international invention patents. Our proprietary biomaterial technologies support a comprehensive range of dental specialties—including orthodontics, periodontics, restorative dentistry, endodontics, prosthodontics, and implantology—while extending into orthopedics, neuroscience, and veterinary medicine.

One of our proudest achievements is our exclusive collaboration with Sigenics in the United States. Through this partnership, our biomaterials have been successfully applied to the encapsulation of brain-computer interface (BCI) chips. In 2022, this technology was implanted into the visual cortex of blind patients, helping restore partial vision and demonstrating the potential of biomaterial innovation to contribute to transformative medical technologies.

Looking ahead, we remain committed to our founding mission: advancing medical biomaterials through continuous innovation, uncompromising quality, and responsible manufacturing. We will continue to provide safer, more effective, and more reliable healthcare solutions for clinicians and patients around the world while contributing to the sustainable development of global healthcare.

Thank you for your trust and support. We look forward to building a healthier future together.